Cargando…

Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes

Medication adherence studies in idiopathic pulmonary fibrosis (IPF) are limited, use cross-sectional designs and report discontinuation rates. We prospectively investigated adherence to pirfenidone in IPF patients using electronic monitoring, which provides insights on whether and when the medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delameillieure, Anouk, Wuyts, Wim A., Pironet, Antoine, Dobbels, Fabienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339768/ https://www.ncbi.nlm.nih.gov/pubmed/35923422 http://dx.doi.org/10.1183/23120541.00030-2022

Ejemplares similares

Patients’ and healthcare professionals’ perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study
por: Delameillieure, Anouk, et al.
Publicado: (2021)

Care programs and their components for patients with idiopathic pulmonary fibrosis: a systematic review
por: Delameillieure, Anouk, et al.
Publicado: (2021)

Behavioural and psychological patterns of patients with idiopathic pulmonary fibrosis: a prospective study
por: Delameillieure, Anouk, et al.
Publicado: (2022)

A New Electronic Monitoring Device to Measure Medication Adherence: Usability of the Helping Hand™
por: De Bleser, Leentje, et al.
Publicado: (2010)

How Accurate Are Electronic Monitoring Devices? A Laboratory Study Testing Two Devices to Measure Medication Adherence
por: De Bleser, Leentje, et al.
Publicado: (2010)

Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models
por: Wuyts, Wim A., et al.
Publicado: (2014)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management
por: van Cleemput, Johan, et al.
Publicado: (2018)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

Clinical Predictors of Survival in Idiopathic Pulmonary Fibrosis
por: Kim, Ji Hye, et al.
Publicado: (2012)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

Predominant dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: to be distinguished from idiopathic pulmonary fibrosis
por: Slabbynck, Hans, et al.
Publicado: (2017)

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
por: Delanote, Isabelle, et al.
Publicado: (2016)

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
por: Stijn, Willems, et al.
Publicado: (2013)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Predictors and changes of physical activity in idiopathic pulmonary fibrosis
por: Badenes-Bonet, Diana, et al.
Publicado: (2022)

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis
por: McDonough, John E., et al.
Publicado: (2018)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Prevalence and Patient-Level Correlates of Intentional Non-Adherence to Immunosuppressive Medication After Heart-Transplantation—Findings From the International BRIGHT Study
por: Marston, Mark T., et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey
por: Cottin, Vincent, et al.
Publicado: (2015)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
por: Goos, Tinne, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Clinical use of biomarkers of survival in pulmonary fibrosis
por: Thomeer, Michiel, et al.
Publicado: (2010)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
por: Wuyts, Wim A., et al.
Publicado: (2022)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis
por: Demonceau, Jenny, et al.
Publicado: (2013)

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
por: Richeldi, Luca, et al.
Publicado: (2018)

Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
por: Dotan, Yaniv, et al.
Publicado: (2020)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients
por: Nili, Mona, et al.
Publicado: (2023)

Dynapenia is highly prevalent in older patients with advanced idiopathic pulmonary fibrosis
por: Bocchino, Marialuisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gadjc6a0qhlr37brlt9jfnc1d1